New oral anticoagulants: Need and challenges in a developing country

Journal of the College of Physicians and Surgeons Pakistan

Volumn 26, Issue 7, 2016, Pages 551-552

  Khan, Maria ^a   Wasay, Mohammad ^b  

^a RASHID HOSPITAL   (United Arab Emirates)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; EDOXABAN; RIVAROXABAN; WARFARIN;

AGING; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DRUG SAFETY; EDITORIAL; HEALTH CARE COST; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIFE EXPECTANCY; NON VALVULAR ATRIAL FIBRILLATION; PAKISTAN; BLEEDING; BLOOD CLOTTING; CHEMICALLY INDUCED; COMPLICATION; DEVELOPING COUNTRY; DRUG COST; DRUG EFFECTS; DRUG INTERACTION; ECONOMICS; ORAL DRUG ADMINISTRATION; RISK FACTOR; STROKE;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DEVELOPING COUNTRIES; DRUG COSTS; DRUG INTERACTIONS; HEMORRHAGE; HUMANS; RISK FACTORS; STROKE;

EID: 84983599836     PISSN: 1022386X     EISSN: 16817168     Source Type: Journal    
DOI: None     Document Type: Editorial

References (5)

1. Goudie B. Near patient monitoring of anticoagulant therapy in general practice. Scottish Med J 2004. 49:70.
2. Connolly, SJ, Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007; 116:449-55.
3. Connolly SJ. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009. 361:1139-51.
4. Granger CB. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981-92.
5. Miller CS. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 2012; 110:453-60.